Clinical Trial Search block Test

ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

ACNS1831

  • Condition(s): Behavioral, Brain Tumor, Low-Grade Glioma, Newly diagnosed, Other, Pilocytic Astrocytoma, Survivorship
  • Phase: III
  • Clinicaltrials.gov ID: NCT03871257

What is the goal of the study?

To determine whether the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior to treatment with carboplatin/vincristine (CV) in previously untreated Neurofibromatosis type 1 (NF1)-associated low-grade glioma (LGG). To determine whether visual acuity (VA) using Teller Acuity Cards (TAC), in patients with NF1-associated LGG within the optic pathway, is better in those treated with selumetinib compared to CV

Who can participate in the study?

Everyone

Study Team: